Skip to main content

Weather alert

Due to Hurricane Isaias, our Patient Service Centers in affected areas may be closed. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational. For site-specific information, please use Find a location and enter your zip code.

Hide
Quest Diagnostics

Data analysis: The superiority of lab data in rare disease patient identification

Data analysis

A major challenge in managing IgA nephropathy (IgAN) is delayed diagnosis. While claims data flags these patients with a broad chronic kidney disease (CKD) diagnosis, it creates critical blind spots.

 

This comparative analysis demonstrates how integrating real-world lab data provides the specific clinical details required to suspect IgAN and prompt further diagnostic steps.

 

See how real-world lab data can provide clinical signals indicating IgAN an average of 2.5 years sooner than the formal diagnosis appears on a claim.

See the value of
real-world lab data in rare disease patient identification

941

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.